Towards cardiovascular risks in children with chronic kidney disease: a prospective cohort study [version 1; peer review: 1 approved with reservations, 1 not approved]

Taghreed Fadhil Al-Doori¹, Abd El-Salam Dawood Al-Ethawi², Jessar Saleem Hasan¹, Ban Adil Al-Kaaby³

¹Nephrology Unit, Central Child Teaching Hospital, Baghdad, 00964, Iraq
²Paediatric Department, Al-Mustansiriyah College of Medicine/Ibn Al-Bittar Centre for Cardiac Surgery, Baghdad, 00964, Iraq
³Paediatric Department, Al-Mustansiriyah College of Medicine/Central Child Teaching Hospital, Baghdad, 00964, Iraq

Abstract

Background: Children with chronic kidney disease (CKD) are at substantially high risk of morbidity and mortality from cardiovascular disease (CVD). Although this issue has been extensively studied in adults, little is known whether similar associations exist in the paediatric population. We therefore aimed to evaluate the cardiac structure and function in children with CKD, and investigate the factors that contribute to the development of CVD.

Methods: A prospective cohort was established following 40 children with CKD treated in the nephrology unit at a high-volume, tertiary, teaching hospital and compared to age- and gender-matched controls of the same number. We reviewed the patients' medical records, assessed growth parameters, measured blood pressure, took blood samples, and performed echocardiography.

Results: More than half of the CKD patients are hypertensive (N = 22; 55%) and were found to have a higher proportion of increased left ventricular mass index (LVMI) (75.5%; P = 0.001). In contrast, we did not find any significant association between CKD and both valvular calcification & left ventricular (LV) fractional shortening (FS) in children (P = 0.314). Furthermore, high LVMI is found to be correlated well with the following: anaemia, hypertension, CKD duration > one year, hyperparathyroidism, estimated glomerular filtration rate (eGFR) < 15ml/minute/1.73 m² and death (P < 0.05).

Conclusions: Despite the fact that LV systolic function is preserved and valvular calcification is usually absent, left ventricular hypertrophy (LVH) is common in children with CKD. Hypertension, anaemia, hyperparathyroidism, as well as the severity and duration of renal impairment, are amongst the additional risk factors that predispose to LVH. We contribute this study to the growing information of the review articles regarding the association between CKD and CVD in
Keywords
Chronic Kidney Disease (CKD), ESRD, Cardiovascular Disease (CVD), Left Ventricular Hypertrophy (LVH), Left Ventricular Mass Index (LVMI), paediatric, children
Introduction

Children with chronic kidney disease (CKD) are at substantially higher risk of morbidity and mortality from cardiovascular disease (CVD). CVD is regarded by many as the most important cause of death among patients receiving chronic renal replacement therapy; accounting for approximately 45 per cent of overall mortality. A Task Force on CVD of the National Kidney Foundation has compared the mortality rate from CVD in dialysis patients (=50 thousand deaths) with those in the general population (=2 million deaths). They showed that annual mortality from CVD is much greater in dialysis patients, in spite of stratification for race, gender, or age group. Two pathological causes of the raised risk for CVD deaths have been identified. First, the high prevalence of CVD in dialysis patients. Second, is the elevated case fatality rate among this group.

Herzog et al. have examined the US Renal Data System between 1977 and 1995. They evaluated outcomes of more than 34 thousand patients on long-term dialysis with myocardial infarction (MI). Interestingly, they found cardiac-related deaths were ≈52 per cent at 2 years and ≈70 per cent at 5 years post-MI follow-up.

Researchers have described three pathological forms of CVD prevalent in patients with CKD. The first one is atherosclerosis which is considered as the primary aetiology of ischemic heart disease (IHD) in that subset of patients. Further, coronary artery plaques, in CKD patients, tend to be more advanced, with higher degrees of calcification and media thickening. The second pathology is an alteration in heart geometry. It includes left ventricular (LV) remodelling, concentric LV hypertrophy (LVH), and eccentric LVH.

In regards to concentric LVH, the LV wall thickness rises to a greater extent than its diameter; while in the eccentric type, the magnitude of LV wall increase is in proportion to the increase in LV diameter. Concentric LVH, on the one hand, is predominantly seen in cases with pressure overload secondary to aortic stenosis, arteriosclerosis, or hypertension. On the other hand, the eccentric form can be depicted in scenarios with volume overload, such as anaemia, fluid retention, and arteriovenous fistulae. The third pathological form is arteriosclerosis – a large vessel disease. This process involves loss of elasticity, vessel remodelling, and development of non-compliant arteries. This results in elevated pulse pressure that, in turn, has been regarded, by many, as a risk factor for CVD deaths in dialysis patients.

Two kinds of risk factors have been identified in CKD patients – traditional and uremia-related ones. The traditional risk factors, that are included in the Framingham Heart Study Offspring Cohort population, include, among others, hyperlipidemia, hypertension, diabetes, male sex, LVH, and smoking. Despite the fact that CKD patients have a higher incidence of many of these risk factors, they are exposed to uremia-related ones as well. A large number of dialysis patients have high levels of oxidative stress, homocysteine, lipoprotein(a), and lipoprotein remnants. Levels of inflammatory markers (e.g. C-reactive protein) and thrombogenic factors (such as fibrinogen) also are elevated. Furthermore, recent studies have shown that hemodialysis patients have a higher prevalence of sleep disorders, including apnea, that might contribute to the elevated risk for CVD.

However, although the issue of CVD risks in CKD patients has been extensively studied and discussed in adults, little is known whether similar associations exist in the paediatric population. The aim of this study, therefore, is to evaluate the cardiac structure & function in children with CKD and investigate for factors that contribute to the development of CVD in that set of patients.

Methods

In this prospective cohort study, we enrolled 45 patients with CKD, treated in the nephrology unit of the Central Child Teaching Hospital-Baghdad, a high-volume, tertiary, teaching hospital over a 13-month period (from October 2016 to November 2017).

We included all the patients attending the unit during the period of the study (the sample size) with the following inclusion criteria in mind: age between 2–14 years, GFR<60 ml/min/1.73 m² for more than 3 months, and absence of confounders, such as myocardial disease (congenital, structural or primary), diabetes mellitus (DM) or corticosteroid use during the period of study. As such, five patients were excluded as two had congenital heart diseases, another two had DM, and one was receiving corticosteroid treatment.

For comparison, we selected a control group of 40 patients (1:1 ratio) who were age- and gender-matched to the study group. Age matching was considered present if the difference was within two years. The controls were patients in the same hospital but with unrelated conditions or diseases. They have been recruited randomly from different units of the hospital. Informed written consent was taken and the following inclusion criteria were considered: normal systemic blood pressure (BP), renal function tests, general urine exam (GUE), and abdominal ultrasound (US) of the genitourinary tract with no clinical evidence of cardiovascular system issues (such as cyanosis, shortness of breath, chest pain, palpitation, and cardiac murmur).

As per this study, CKD is defined as renal damage or glomerular filtration rate (GFR) of less than 60 ml/minute/1.73 m² body surface area (BSA) for three months, regardless of the cause.

For all the patients (cases and controls) included in this study, we measured the following parameters: body weight (BW), height (Ht), height percentile, body mass index (BMI) (BW/Ht²), and surface area (SA). The latter is calculated as follows: SA = Square Root [BW (kg) x Ht (cm) / 3600].

The patients’ medical records were reviewed for the presence of primary renal disease, its duration, underlying cause, and the medications used. In regards to the cause, we categorized the patients into four groups. Group I: congenital renal anomalies, group II: acquired renal diseases, group III: hereditary nephropathies and group IV: CKD of unknown aetiology. We
recorded the mode of treatment into one of three modalities: hemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD) or conservative treatment. The outcome of the patients, during the period of the study, have been identified.

On the day of the echocardiographic study, we took the following blood samples for each patient: haemoglobin, blood urea, serum creatinine, serum calcium and serum phosphorus. All these tests were analyzed using the standard, local laboratory methods.

The estimated GFR (eGFR) has been calculated using Schwartz Formula\(^1\) (eGFR= \(\text{Height (cm)/serum creatinine (mg/dl)*K}\)). Where K is a “constant” based on age as follows: 0.70 in adolescent boys; 0.55 in adolescent females & children; 0.45 in full term infants and 0.33 in preterm newborns.

According to the eGFR, we divided the patients into two groups: those \(<15\text{ ml/min/1.73 m}^2\) and those \(\geq 15\text{ ml/min/1.73 m}^2\). Furthermore, we divided the duration of the CKD into two groups–either within one year or those more than or equal to one year.

Blood pressure was measured three times during the same day; in sitting position and using mercurial sphygmomanometer with an appropriate cuff size\(^12\). We took the average of the three measurements and compare the results to nomograms. Hypertension is said to be present when the averaged systolic blood pressure (SBP) and or diastolic blood pressure (DBP) equal to or exceeded 95\(^{th}\) percentile for sex, age & height\(^12\).

Anaemia is defined as a haemoglobin level of less than 11 g/dl in prepubertal children with CKD\(^11\).

Intact parathyroid hormone (iPTH) was assessed using a Cobas e 411 Analyzer (Roche Diagnostics) at a local private lab. Hyperparathyroidism is said to be present when the iPTH exceeds 65 pg/ml\(^13\).

Two board-certified, pediatric cardiologists performed echocardiographic assessments using a Philips CX50 Ultrasound Machine (Philips Healthcare, USA) with the S5-1 transducer. They examined for valvular calcification using 2D Mode; while M-Mode has been used to assess the following: Interventricular Septum thickness in diastole (IVSd), Left Ventricular Internal Diameter in diastole (LVIDd), Left Ventricular Internal Diameter in systole (LVIDs) and Left Ventricular Posterior Wall in diastole (LVPWd). A built-in software tool was used to calculate the fractional shortening (FS %) \([\text{LVIDd – LVIDs}) / \text{LVIDd}*100]\). Left Ventricular Mass (LVM) was calculated using a computerized Microsoft Access 2016 model using Devereux & Reichek cube formula\(^14\): \(\text{LV Mass} = 0.8 \times 1.04 \times (\text{LVIDd + LVPWd + IVSd})^{3} - \text{LVIDd}^{3} + 0.6\). The calculated LVM is then indexed to body surface area (LVMI).

For this study an FS of 25–43% was considered to be a normal value. However, for the IVSd, LVIDd, LVIDs, and LVPWd we depend on values indexed to body surface area according to Park 2008\(^13\).

Left ventricular hypertrophy (LVH) is defined as LVMI greater than the 95\(^{th}\) percentile for gender and age\(^16\).

Statistical analysis was performed with IBM SPSS Statistics 23.0. Suitable graphs & tables were used to describe the data. Student’s T-test was used for comparison between continuous variables. Chi-square & Fisher’s exact tests were used to examine qualitative and frequency data and to find the relation between risk factors and different outcomes. P value < 0.05 was considered significant.

**Results**

The cohort consisted of 80 patients divided into two groups: 40 children with CKD (cases group) and 40 children without CKD (controls group) (Datasets 1 & 2).

Some of the general characteristics of the study population are shown in Table 1.

**Blood pressure**

Among the study patients, 72.5% were normotensive. However, all the control group were normotensive and 55% of cases group were hypertensive with a significant association between CKD & high blood pressure (\(P = 0.001\)) (Figure 1).

**Haemoglobin level**

About 40% of the study population, 7.5% in the control group and 72.5% of the cases group were anaemic (Figure 2). There is a significant association between CKD and anaemia (\(P = 0.001\)).

### Table 1. The study population: general characteristics.

|                  | Cases Group: 40 cases | Controls Group: 40 cases |
|------------------|-----------------------|--------------------------|
| **Age (years):** | Range                 | 2 – 14                   |
|                  |                       | 2 – 14                   |
|                  | Mean, 95% CI          | \(8.59, 7.53-9.65\)     |
|                  |                       | \(7.45, 6.48-8.42\)     |
| **Gender**       | Males: 19 (47.5%)     | Male: 19 (47.5%)         |
|                  | Females: 21 (52.5%)   | Females: 21 (52.5%)      |
| **BMI (Kg/m²):** | Range                 | 12.1 – 34                |
|                  |                       | 11.1 – 33                |
|                  | Mean, 95% CI          | \(16.84, 15.65-18.03\) |
|                  |                       | \(17.05, 15.84-18.26\)  |

**Abbreviations:** BMI: Body Mass Index = body weight (Kg)/ Height\(^2\) (m\(^2\)); CI: Confidence Interval
Biochemical and hormonal studies
With regards to the biochemical & hormonal studies, blood urea, serum (S.) creatinine, S. phosphorus (Po), Calcium * Phosphorus (Ca * Po) product and parathyroid hormone (PTH) levels were higher amongst patients in the case group than in the controls. However, S. Ca is lower in the cases (Table 2).

Most of the patients in the cases group had CKD for more than a year (62.5%), and the majority (82.5%) were alive during the period of the study (Figure 3 & Figure 4). More than half of them were treated conservatively, however, other modalities were utilized (Figure 5).

Congenital renal abnormalities constitute 37.5% of the causes of CKD in this study, with vesicoureteral reflux (VUR) being the most common anomaly seen (32.5%) (Table 3).

Echocardiographic findings
CKD Patients were found to have a higher left ventricular mass index (LVMI) when compared to the control group (75.5% vs. 0%) with a statistically significant association between CKD and LVH (P = 0.001). However, we did not find any significant association between CKD and both valvular calcification, and fractional shortening (FS) (P = 0.314) (Table 4).

In terms of the cardiac measurements, interventricular septal diameter in diastole (IVSd), left ventricular posterior wall diameter in diastole (LVPWd), and LVMI are higher (P < 0.05) among CKD patients than the controls. On the other hand, there is no statistical significant difference (P > 0.05) in term of FS, LV internal diameter in diastole (LVIDd) and LV internal diameter in systole (LVIDs) between the CKD patients and the controls (Table 5).
Table 2. The Study Population: Serum biochemical & PTH levels.

| Biochemical test         | Cases Group: Mean (95% CI) | Controls Group: Mean (95% CI) | P-Value |
|--------------------------|----------------------------|-------------------------------|---------|
| Bl. Urea (mmol/l)        | 24.97 (21.22-28.72)        | 4.44 (4.02-4.86)              | 0.001   |
| S. Creatinine (µmol/l)   | 443.27 (364.84-521.70)     | 62.26 (59.28-65.24)           | 0.001   |
| S. Ca (mg/dl)            | 7.78 (7.44-8.12)           | 9.19 (8.97-9.41)              | 0.001   |
| S. Po (mg/dl)            | 6.14 (5.45-6.83)           | 4.01 (3.81-4.21)              | 0.001   |
| Ca*Po (mg²/dl²)          | 48.11 (42.22-54.00)        | 36.92 (34.77-39.07)           | 0.001   |
| PTH (pg/ml)              | 451.93 (434.86-469.00)     | 43.99 (38.68-49.30)           | 0.001   |

Abbreviations: Bl. – Blood; Ca – Calcium; CI – Confidence Interval; Po – Phosphorus; PTH – Parathyroid hormone; S. – Serum

Figure 3. Cases group: duration of chronic kidney disease.

Figure 4. Cases group: outcome of chronic kidney disease patients.
Table 4. The Study Population: Some Echocardiographic Features.

|                        | Cases Group (%) | Control Group (%) | P-Value |
|------------------------|-----------------|-------------------|---------|
| High LVMI              |                 |                   |         |
| Positive               | 27 (75.5)       | 0 (0)             | 0.001   |
| Negative               | 13 (24.5)       | 40 (100)          |         |
| Valvular Calcification |                 |                   |         |
| Positive               | 1 (2.5)         | 0 (0)             | 0.314   |
| Negative               | 39 (97.5)       | 40 (100)          |         |
| Low FS                 |                 |                   |         |
| Positive               | 1 (2.5)         | 0 (0)             | 0.314   |
| Negative               | 39 (97.5)       | 40 (100)          |         |

Abbreviations: FS – Fractional Shortening; LVMI – Left Ventricular Mass Index.

High LVMI was seen in patients with all of the following: anaemia, hypertension, CKD duration > one year, high PTH and eGFR < 15 ml/min/1.73 m². All the patients who died, as well as those with acquired or unknown cause of CKD, have increased LVMI. On the other hand, no association has been discovered between gender or mode of treatment, and the risk of high LVMI (Table 6).

Discussion

In this study, 19 patients (47.5%) – in the cases group – were males and 21 cases (52.5%) were females; with a male: female ratio of 0.9: 1. However, this contradicts results obtained in other studies, like Harambat et al., where the higher prevalence of CKD in males has been attributed to the higher frequency of congenital abnormalities of the kidney and urinary tract (CAKUT) in this group.
Table 5. The Study Population: Comparison of Certain Echocardiographic Measurements.

|                    | Cases Group: Mean (95% CI) | Controls Group: Mean (95% CI) | P-Value |
|--------------------|-----------------------------|-------------------------------|---------|
| FS%                | 38.88 (36.11-41.65)         | 37.77 (35.32-40.22)          | 0.556   |
| IVSd (mm)          | 10.48 (9.17-11.79)          | 6.43 (6.05-6.81)             | 0.001   |
| LVPWd (mm)         | 10.7 (9.11-12.29)           | 6.21 (5.85-6.57)             | 0.001   |
| LVIDs (mm)         | 22.3 (20.04-24.56)          | 21.87 (20.51-23.23)          | 0.753   |
| LVIDd (mm)         | 35.3 (32.17-38.43)          | 32.57 (31.13-34.01)          | 0.125   |
| LVMI (gm/m²)       | 150.1 (112.42-187.78)       | 54.71 (48.69-60.73)          | 0.001   |

Abbreviations: CI – Confidence Interval; FS – Fractional Shortening; IVSd – Interventricular Septal thickness in Diastole; LVIDd – Left Ventricular Internal Diameter in Diastole; LVIDs – Left Ventricular Internal Diameter in Systole; LVMI – Left Ventricular Mass Index; LVPWd – Left Ventricular Posterior Wall in Diastole

Table 6. Cases Group: Association between LVMI and certain details.

|                    | Cases Group |              |              | P-Value |
|--------------------|-------------|--------------|--------------|---------|
|                    | High LVMI (%) | Normal LVMI (%) |              |         |
| Gender             | Male        | 12 (63.2)    | 7 (36.8)     | 0.577   |
|                    | Female      | 15 (71.4)    | 6 (28.6)     |         |
| Hemoglobin         | Normal      | 3 (27.3)     | 8 (72.7)     | 0.001   |
|                    | Anaemic     | 24 (82.8)    | 5 (17.2)     |         |
| Blood Pressure     | Normotensive| 7 (38.9)     | 11 (61.1)    | 0.001   |
|                    | Hypertensive| 20 (90.9)    | 2 (9.1)      |         |
| Duration of CKD    | ≤ one year  | 7 (46.7)     | 8 (53.3)     | 0.029   |
|                    | > one year  | 20 (80.0)    | 5 (20.0)     |         |
| Mode of treatment  | Conservative| 11 (52.4)    | 10 (47.6)    | 0.094   |
|                    | CAPD        | 15 (83.3)    | 3 (16.7)     |         |
|                    | Hemodialysis| 1 (100.0)    | 0 (0)        |         |
| PTH                | Normal      | 1 (10.0)     | 9 (90.0)     | 0.001   |
|                    | High        | 26 (86.7)    | 4 (13.3)     |         |
| eGFR               | < 15 ml/min/1.73 m²| 18 (85.7) | 3 (14.3) | 0.01 |
|                    | ≥ 15 ml/min/1.73 m²| 9 (47.4) | 10 (52.6) |         |
| Outcome            | Live        | 20 (60.6)    | 13 (39.4)    | 0.043   |
|                    | Death       | 7 (100.0)    | 0 (0)        |         |
| Causes of CKD      | Congenital renal abnormality| 8 (53.3) | 7 (46.7) |         |
|                    | Acquired renal disease| 4 (100.0) | 0 (0)        |         |
|                    | Hereditary Nephropathy| 5 (45.5) | 6 (54.5) |         |
|                    | Unknown cause| 10 (100.0) | 0 (0)        |         |

Abbreviations: CAPD – Chronic Ambulatory Peritoneal Dialysis; CKD – Chronic Kidney Disease; eGFR - Estimated Glomerular Filtration Rate; LVMI – Left Ventricular Mass Index; PTH – Parathyroid Hormone

Body mass index (BMI) does not reflect body composition. Furthermore, a patient who has an appropriate BMI for age might not have a typical body composition. In this study, BMI shows no significant difference (P = 0.812) between the cases and the controls groups. This is consistent with previous studies.

In terms of blood pressure, 55% of patients in the cases group were hypertensive (P = 0.001), though other studies show a higher prevalence. Many factors contribute to the raised incidence of hypertension in CKD patients. They include sodium retention, increased activity of the renin-angiotensin-aldosterone system,
an exaggerated activity of the sympathetic nervous system, secondary hyperparathyroidism, deficient nitric oxide and endothelium-mediated vasodilation, and treatment with erythropoietin – if present\textsuperscript{10–24}. In addition, hypertension might be a causative (e.g. hypertensive nephrosclerosis) or contributory pathology in the development of CKD\textsuperscript{25}.

Anaemia was found in 29 patients (72.5\%) in the cases group (P = 0.001). This is consistent with results obtained by other researchers\textsuperscript{26–29}. A hyperproliferative state is thought to be the underlying mechanism. The latter might result from the following: First, changes in iron metabolism which is hepcidin-induced that causes decreased iron absorption from the gut, in addition to iron macrophage trapping\textsuperscript{30,31}. Second, shortened red blood cells (RBC) survival, resulting from raised macrophage activity\textsuperscript{32}. Third, a high apoptotic death of RBC precursors in the bone marrow\textsuperscript{33}. Finally, a “relative” decline in erythropoietin (EPO) production\textsuperscript{34}.

In the United States and Europe, many studies have shown that congenital genitourinary anomalies account for almost 60\% of CKD cases in younger children; while glomerular diseases are more common in older children & adolescents\textsuperscript{35–36}. In the first subset of patients, obstructive uropathy (21\%) is the most common pathology, followed by renal dysplasia/hypoplasia (18\%) and reflux nephropathy (8\%). On the other hand, focal segmental glomerulosclerosis (FSGS) is the most prevalent glomerular lesion, accounting for 9\% of cases. However, in our study, congenital renal anomalies were found in 15 patients (37.5\%) with vesicoureteral reflux (VUR) being the most common pathology (N = 13; 32.5\%). Both FSGS and rapidly progressive glomerulonephritis (RPGN) have the same prevalence as a cause of acquired glomerular diseases (N = 2; 5\%).

Left ventricular hypertrophy (LVH) is regarded by many as an adaptive response to long-lasting volume or pressure overload. Initially, it is beneficial because it allows for increasing work capacity, maintains systolic function and decreases energy consumption & wall stress. However, with time, LVH becomes detrimental as it alters LV diastolic function, decreases coronary perfusion reserve and predisposes to arrhythmias & sudden death\textsuperscript{37–39}. Some researchers\textsuperscript{40,41} have found that an increase in LV mass by 1 gm/m\textsuperscript{2}/month is associated with a 62\% rise in the risk of fatal and non-fatal cardiovascular events in dialysis patients. In our study, all the seven children who died had LVH.

In this study, CKD patients had a thicker diastolic interventricular septum (IVSd) (10.5 vs 6.4, P = 0.001), diastolic LV posterior wall (LVPWd) (10.7 vs 6.2, P = 0.001) and LV Mass Index (LVMI) (150.1 vs 54.7, P = 0.001) in comparison to controls. Furthermore, LVMI was increased in 27 (75.5\%) patients in the cases group (P = 0.001). These results are consistent with those obtained by Malikenas et al.\textsuperscript{42} and van Huis et al.\textsuperscript{43}.

Despite the fact that LV systolic dysfunction carries a poor prognosis in end-stage renal disease (ESRD) in adults, and is considered by many as an important co-morbidity, LV function is usually well preserved in the pediatric population\textsuperscript{44}. In our study, only one case (2.5\%) shows low LV fractional shortening with no statistically significant association between CKD & systolic dysfunction. This is consistent with other researchers in other parts of the world\textsuperscript{45,46}. It may be that LV systolic dysfunction only becomes clinically evident after a long period of time.

Many studies have shown that vascular & valvular calcification is associated with cardiovascular disease, which is by far the most common cause of death in CKD\textsuperscript{47–48}. Calcification is prevalent among CKD patients, particularly those on dialysis. Prevalence is highest among patients with lower eGFR, and it is presumed that, as the eGFR declines, the prevalence as well as the severity of the calcification rise\textsuperscript{47–49}. It has been seen that 80\% of dialysis patients show calcification versus 47–83\% among those who are not on dialysis\textsuperscript{50–56}.

In our study however, valvular calcification was present in only one patient (2.5\%). This low prevalence can be explained as follows: first, all the studied patients are under the age of 14 years. Knowing that calcification is a slowly-developing process that takes time, the younger the patient, the less likely this pathology can be clinically detected. This was shown in a comprehensive systematic meta-analysis review of 30 studies over a 20-year-period that demonstrated that the age of the patient is one of the most important factors associated with calcification in CKD\textsuperscript{50}. Second, we relied on echocardiography in detection and quantification of valvular calcification. However, computed tomography (CT), using special software & scanners is considered, by many, as a more sensitive tool in this context, especially when coronary arteries calcification needs to be assessed as well\textsuperscript{57–58}. Third, preventive measures, in our centre, may play a role, which includes the cautious use of vitamin D therapy and achieving net calcium balance by using non-calcium-containing phosphate binders or by modifying the dialysate bath calcium concentration in dialysis patients\textsuperscript{59,60}.

In adults, many studies have shown an association between LVH and parathyroid hormone (PTH) concentration in patients with CKD\textsuperscript{51,62}. The underlying mechanisms of PTH-induced LVH include an indirect effect – by elevating systemic blood pressure, and a direct effect of this hormone on the cardiac myocytes\textsuperscript{63}. Furthermore, in vitro studies have revealed that PTH has inotropic, chronotropic as well as hypertrophic effects on cardiac cells\textsuperscript{64,65}. In this study, high LVMI was present in 26 out of 30 cases (86.7\%) with high PTH. The latter is consistent with results obtained by Mitsnefes et al.\textsuperscript{66} who showed that raised PTH level is associated with LVH progression in CKD stages 2–4.

In our study, LVH was found in 24 out of 29 cases (82.8\%) with anaemia. This is consistent with most studies in children, which revealed a significant relationship between anaemia and raised LVMI\textsuperscript{67–69}. However, recent studies in adults with mild-moderate CKD or on long-term dialysis showed that increasing haemoglobin (Hb) levels was not associated with LVH regression\textsuperscript{70–72}. Therefore, the authors have suggested that the relationship between LVH and anaemia could not be causal. Of note, these studies recruited subjects with relatively mild anaemia and,
thus, not able to answer the question of whether correcting more severe anaemia may lead to a decline of LVMI. On the contrary, Morris et al.30 observed a substantial reduction in LVMI with the treatment of severe anaemia in children on dialysis.

Regarding the mode of treatment of CKD and its association with LVH, research42,75 has shown that the prevalence of LVH varies with the mode of treatment of CKD; being 16–31% in those with eGFR > 30 ml/min/1.73 m², 60–75% when renal replacement therapy is started, and 70–90% in patients with regular dialysis. Our study, however, reveals rather different statistics. Up to 50% of patients on conservative treatment had LVH. Refusal to start renal replacement therapy by the family has caused a substantial delay in the treatment and this might be the most likely explanation of these figures.

The lower the eGFR, the more likelihood of having LVH. In this study, more than 85% of patients with eGFR of < 15 ml/min/1.73 m², in comparison to 47% of those whom eGFR ≥ 15 ml/min/1.73 m². These findings are consistent with those of researchers elsewhere in the world44,74,75.

Malikenas et al.42 have noticed an association between the CKD causes and LVH. They found that patients with acquired renal diseases had significantly higher LVMI than those with congenital renal abnormalities. In our study, 100% of patients with acquired causes had high LVMI versus 53% with congenital anomalies. An interesting point, however, is that 100% of those with unknown cause of CKD had LVH. This can be explained by the fact that these cases are usually presented late to our centre.

**Limitations of the study**

1. Because of time constraints, only one assessment has been done to both the cases and the controls groups. We believe that with frequent, lengthy follow up on the cases arm, many parameters would change with time, such as LV mass & function, calcification, outcome, etc. Thus, an extension of this study is in progress to include months of follow-up.

2. To detect cardiovascular calcification, we depended on echocardiographic detection. However, computed tomography (CT) is considered, by many, as a more sensitive tool in this context.

3. Only left ventricular (LV) systolic function has been assessed, using LV fractional shortening (FS). While neither LV diastolic, nor right ventricular (RV) function has been evaluated, though we think both might be influenced in patients with CKD.

**Conclusions**

Despite the fact that LV systolic function is usually well-preserved & valvular calcification is usually absent, LVH is common in children with CKD. LVH is associated with higher mortality in that subset of patients; with the severity & duration of renal impairment, hypertension, anaemia, and hyperparathyroidism are amongst the additional risk factors that predispose to LVH. We contribute this study to the growing information of the review articles regarding the association between CKD and cardiovascular complications in paediatrics. However, additional clinical trials are urgently required with a goal to reduce CVD in CKD children.

**Data availability**

All the raw data required for reproducibility of this study are available on Open Scientific Framework

OSF. Dataset 1 & 2: Replication Data for: Toward Cardiovascular Risks in Children with Chronic Kidney Disease, https://doi.org/10.17605/OSF.IO/WY28B

Data is available under a CCO 1.0 Universal license

**Ethical approval**

The Institutional Ethics Committee of the Paediatric Department, College of Medicine, Al-Mustansiriyah University has reviewed & discussed the initial application to conduct this study, informed about its progress, and any revision in the protocol and patient information/informed consent. The Committee has received & approved the final report of the study on April, 2018.

None of the investigators participating in this study took part in the decision making & voting for this study.

**Patients’ consent**

Informed written consent was taken from the parents of the children to participate in this study and for publication of the clinical details.

**Grant information**

The author(s) declared that no grants were involved in supporting this work.

**References**

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(3 Suppl 3): S112–9.
2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998; 339(12): 799–805.
3. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 2003; 41(9 Suppl): 11–7.
4. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000; 15(2): 218–23.
conditions: new insights into pathogenesis. Semin Nephrol. 2006; 26(1): 33–7.

51. Fukagawa M, Kazama J, et al.: The making of a bone in blood vessels: from the soft shell to the hard bone. Kidney Int. 2007; 72(S2): S33–4.

52. Jablonski KL, Chonchol M: Vascular calcification in end-stage renal disease. Hemodial Int. 2013; 17 Suppl 1: S17–21.

53. Moe BM, O’Neill KD, et al.: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002; 61(2): 638–47.

54. Shanahan CM, Crouthamel MH, Kapustin A, et al.: Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4(6): 1106–14.

55. Vervloet M, Cozzolino M: Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2017; 91(4): 806–17.

56. Vervloet M, Cozzolino M: Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2017; 91(4): 806–17.

57. Agaton AS, Jarowetz WR, Hildner FJ, et al.: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1995; 25(4): 827–32.

58. Mao SS, Pal RS, McKay, et al.: Comparison of coronary artery calcium scores between electron beam computed tomography and 64-multidetector computed tomographic scanner. J Comput Assist Tomogr. 2009; 33(2): 175–8.

59. Reynolds JL, Ioannides AJ, Sipper JP, et al.: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004; 15(11): 2857–67.

60. Stemvinkel P, Ketteler M, Johnson RJ, et al.: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—its good, the bad, and the ugly. Kidney Int. 2005; 67(4): 1216–33.

61. London GM, De Vernejoul MC, Fabiani F, et al.: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int. 1987; 32(6): 900–7.

62. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999; 56(2): 383–92.

63. Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on rat heart cells. J Clin Invest. 1981; 67(4): 1215–27.

64. Katoch Y, Klein KL, Kaplan RA, et al.: Parathyroid hormone has a positive inotropic action in the rat. Endocrinology. 1981; 109(6): 2262–4. PubMed Abstract | Publisher Full Text

65. Mitsnefes MM, Kimball TR, Kurlat J, et al.: Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr. 2006; 149(5): 671–5. PubMed Abstract | Publisher Full Text

66. El-Husseini AA, Sheehaha HA, Hassan NA, et al.: Echocardiographic changes and risk factors for left ventricular hypertrophy in children and adolescents after renal transplantation. Pediatr Transplant. 2004; 8(3): 249–54. PubMed Abstract | Publisher Full Text

67. Matteucci MC, Wuhl E, Picca S, et al.: Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol. 2006; 17(1): 218–28. PubMed Abstract | Publisher Full Text

68. Mitsnefes MM, Daniels SR, Schwartz SM, et al.: Severe left ventricular hypertrophy in pediatric dialysis: presence and predictors. Pediatr Nephrol. 2000; 14(10–11): 898–902. PubMed Abstract | Publisher Full Text

69. Foley RN, Parfrey PS, Morgan J, et al.: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000; 58(3): 1295–303. PubMed Abstract | Publisher Full Text

70. Levin A, Djurdjevic O, Thompson C, et al.: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005; 46(5): 799–811. PubMed Abstract | Publisher Full Text

71. Paciotti S, Cassottana P, Bellino D, et al.: Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis. 2002; 40(4): 728–36. PubMed Abstract | Publisher Full Text

72. Roger SD, McMahon LP, Clarkson A, et al.: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4); results of a randomized clinical trial. J Am Soc Nephrol. 2004; 15(1): 148–56. PubMed Abstract | Publisher Full Text

73. Morris KP, Skinner JR, Hunter S, et al.: Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uremia? Arch Dis Child. 1984; 71(2): 119–22. PubMed Abstract | Publisher Full Text | Free Full Text

74. Foley RN, Parfrey PS, Harrett JD, et al.: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47(1): 186–92. PubMed Abstract | Publisher Full Text

75. London GM, Pannier B, Guerin AP, et al.: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12(12): 2759–67. PubMed Abstract

76. AL-ETHAWI AESD: Replication Data for: Toward Cardiovascular Risks in Children with Chronic Kidney Disease. 2018. http://www.doii.org/10.17605/OSF.IO/WY28B
Open Peer Review

Current Peer Review Status: ✗ ✗

Version 1

Reviewer Report 04 May 2021

https://doi.org/10.5256/f1000research.17341.r83112

© 2021 Primack W. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

William Primack

Nephrology Division, University of North Carolina, Chapel Hill, NC, USA

Al-Doori et al. report on echocardiographic findings on a cross-sectional (not prospective) cohort of children aged 2-14 with CKD. Their principal finding confirms other studies showing an association between the duration of hypertension and increased LVMI. They also find an association between increased LVMI and anemia, duration of CKD, and elevated PTH.

The authors do a quite comprehensive review of the literature on cardiovascular disease and CKD, but nearly all the articles report on findings in adults. Since this article was submitted 2 ½ years ago there have been several studies and reviews published on CV disease and pediatric CKD. Several are listed at the bottom of this review.

I commend the authors for performing the study in an area of limited resources.

The authors might consider performing multivariate analyses of their data to see if, for example, the degree of anemia is better correlated with increased LVMI apart from hypertension or similarly if duration of CKD, eGFR, or PTH levels are independently associated with increased LVMI.

Nearly all the data in the figures could better presented in tabular form with means and S.D. or S.E. The authors should consider reporting in the baseline data whether any of the study patients were receiving EPO or antihypertensives.

Mortality in the studied cohort was high (18% in 13 months). Were any of the deaths related to CV issues? Were any of the deceased study patients autopsied and, if so, were the echocardiographic findings of increased LVMI (and no calcifications) in all who died supported by the autopsy results?

By the time this study was done, the Fifth Report on Hypertension in Children had been published and should have been the reference values used, as was the modified Schwartz equation for eGFR based on the CKIDS data.

If the authors are willing/able to do a careful statistical analysis as mentioned above, this paper
would have more value.

A couple of thoughts:

1. How were the authors able to identify the duration of kidney disease in those patients with an unknown cause since they comment that this group often presented later in the course of their CKD?

2. Why do patients with hereditary nephropathy (I assume most with cytinosis and not genetically associated FSGS.), have less frequent elevated LVMI despite having CKD from birth?

Several recent references (via Pubmed):

Cardiovascular risk factors in children on dialysis: an update.
Querfeld U, Schaefer F.
Pediatr Nephrol. 2020 Jan;35(1):41-57. doi: 10.1007/s00467-018-4125-x. Epub 2018 Oct 31. PMID: 30382333

Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study.
Sethna CB, Ng DK, Jiang S, Saland J, Warady BA, Furth S, Meyers KE.
Pediatr Nephrol. 2019 Aug;34(8):1403-1412. doi: 10.1007/s00467-019-04229-3. Epub 2019 Mar 22. PMID: 30903375

Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease.
Villain C, Metzger M, Combe C, Fouque D, Frimat L, Jacquelinet C, Laville M, Briançon S, Klein J, Schanstra JP, Robinson BM, Mansencal N, Stengel B, Massy ZA.
Nephrol Dial Transplant. 2020 May 1;35(5):827-836. doi: 10.1093/ndt/gfy277. PMID: 30169874

Adiposity, Sex, and Cardiovascular Disease Risk in Children With CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study.
Brady TM, Roem J, Cox C, Schneider MF, Wilson AC, Furth SL, Warady BA, Mitsnefes M.
Am J Kidney Dis. 2020 Aug;76(2):166-173. doi: 10.1053/j.ajkd.2020.01.011. Epub 2020 May 7. PMID: 32389356

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Partly

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Glomerular disease, workforce, communication

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 14 Jun 2021

**Abd El-Salam El-Ethawi**, dr.ethawi@gmail.com, Iraq

Thanks a lot for your revision and feedback.
We do agree with most of your points. It was actually initial results of that cohort study.
We are working currently on the final version of it and we will be honoured to have you as a reviewer.

Thanks again; your time & effort are massively appreciated.

Al-Ethawi (Corresponding author)

**Competing Interests:** No conflict of interest

Reviewer Report 11 April 2019

https://doi.org/10.5256/f1000research.17341.r46500

© 2019 Mathew R. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Roy O. Mathew**
Division of Nephrology, Department of Medicine, Columbia VA Health Care System, Columbia, SC, USA

Fadhil Al-Doori *et al.* have written a report of a prospective cohort analysis of echocardiographic features in CKD. The main finding is that of greater LVMI in patients with CKD that seems to correlate with duration of CKD and lack of significant valvular calcification.

The study design is reported as prospective cohort but there was no clear prospective analysis completed. Most of the analyses demonstrated is cross sectional. In the limitations section it is
mentioned that repeated analyses to assess changes over time is planned. It is not clear to me why this preliminary analysis would be submitted with very inconclusive data.

Many issues with presentation are present:

**Introduction:**
The entire introduction is about adult CVD with only a statement in the last paragraph that little is known about CVD in pediatric CKD. There needs to be more background about pediatric CKD.

It's not clear to me why diastolic function and LV EF were not available. This seems to be a routine parameter in most echo readings. That needs to be explained in the methods section as well as the limitation section. Was it just not recorded for the study or was it actually not in the echo report - the echocardiographer never calculated those values?

**Results:**
There are far too many sections describing baseline parameters, as well figures and graphs. Figures 1-5 and Tables 2 and 3 all need to be condensed into Table 1. Then a single section can speak to background features and lab values. Many of the lab values are not surprising in terms of differences between CKD and normal - so not clear individual sections need to be dedicated to how each lab value is different between cases and controls.

The meat of the study should be in the Echo findings.

What are the differences between cases and controls? You can subsequently look at differences between your eGFR classifications (< and >= 15) and duration of CKD (< and >= 1yr). These are the interesting findings.

You have an outcome of death and it seems awkward to have the outcome as a predictor in Table 6. It seems more appropriate to perform a multivariate analysis of death as an outcome and see how echocardiographic parameters compare to CKD and HTN and other lab parameters to predict death.

**Discussion:**
The first half of the discussion is spent describing results (which should not be there) and talking about biochemical abnormalities in CKD which is already well known. Essentially the appropriate discussion section should starting at page 9 paragraph 4 - which starts "Left Ventricular Hypertrophy...."

**Overall -** This manuscript seems premature especially since follow up data is planned. It is not clear to me what can be presented except a very brief report with the follow up data.

I would recommend revising this when the follow up data is available.

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**Is the study design appropriate and is the work technically sound?**
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Chronic kidney disease, cardiovascular disease in chronic kidney disease, community acquired acute kidney injury.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

---

### Author Response 03 May 2019

**Abd El-Salam El-Ethawi**, Paediatric Cardiologist. Al-Mustansiriyah College of Medicine, Baghdad, Iraq

Dear Dr Mathew,
Thanks a lot for your scientific critical appraisal. We appreciate your time spent on reading our manuscript.
We do agree with most of your comments and suggestions. They will, definitely, be addressed in the upcoming version - when the follow up data will be available.
Looking forward to having your "next go" after revision.
Sincerely,
Al-Ethawi

**Competing Interests:** Nothing to declare
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com